Mashar Meghavi, Mashar Ruchir, Hajibandeh Shahab
Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Department of General Surgery, Hereford County Hospital, Hereford, HR1 2BN, UK.
Int J Colorectal Dis. 2019 May;34(5):773-785. doi: 10.1007/s00384-019-03277-3. Epub 2019 Mar 23.
To compare outcomes of uncovered stent and covered stent in management of large bowel obstruction secondary to colorectal malignancy.
We conducted a search of electronic databases identifying studies comparing outcomes of uncovered and covered stents in management of large bowel obstruction secondary to colorectal malignancy. The Cochrane risk-of-bias tool and the Newcastle-Ottawa scale were used to assess the included studies. Random or fixed effects modelling were applied as appropriate to calculate pooled outcome data.
One randomised controlled trial (RCT) and nine observational studies, enrolling 753 patients, were identified. Uncovered stent was associated with lower risks of complications (RR 0.57 95% CI 0.44-0.74, P < 0.0001), tumour overgrowth (RR 0.29 95% CI 0.09-0.93, P = 0.04), and stent migration (RR 0.29 95% CI 0.17-0.48, P < 0.00001); longer duration of patency (MD 18.47 95% CI 10.46-26.48, P < 0.00001); lower need for stent reinsertion (RR 0.38 95% CI 0.17-0.86, P = 0.02); and higher risk of tumour ingrowth (RR 4.53 95% CI 1.92-10.69, P = 0.0008). Rates of technical success (RR 1.02 95% CI 0.99-1.04, P = 0.21), clinical success (RR 1.03 95% CI 0.98-1.08, P = 0.32), perforation (RD 0.01 95% CI - 0.03-0.02, P = 0.65), bleeding (RD 0.00 95% CI - 0.03-0.03, P = 0.98), stool impaction (RR 0.56 95% CI 0.12-2.04, P = 0.38) and stent obstruction (RR 2.23 95% CI 0.94-5.34, P = 0.97) were similar.
Our results suggest that uncovered stents are superior as indicated by fewer complications, lower rates of stent migration, longer duration of patency and a reduced need for stent reinsertion. The best available evidence is mainly derived from non-randomised studies; there is a need for more RCTs.
比较裸支架和覆膜支架在治疗结直肠癌继发大肠梗阻中的效果。
我们检索了电子数据库,以确定比较裸支架和覆膜支架治疗结直肠癌继发大肠梗阻效果的研究。使用Cochrane偏倚风险工具和纽卡斯尔-渥太华量表来评估纳入的研究。根据适当情况应用随机或固定效应模型来计算汇总结果数据。
确定了一项随机对照试验(RCT)和九项观察性研究,共纳入753例患者。裸支架与较低的并发症风险(RR 0.57,95%CI 0.44 - 0.74,P < 0.0001)、肿瘤过度生长风险(RR 0.29,95%CI 0.09 - 0.93,P = 0.04)和支架迁移风险(RR 0.29,95%CI 0.17 - 0.48,P < 0.00001)相关;通畅持续时间更长(MD 18.47,95%CI 10.46 - 26.48,P < 0.00001);支架再次置入的需求更低(RR 0.38,95%CI 0.17 - 0.86,P = 0.02);以及肿瘤长入的风险更高(RR 4.53,95%CI 1.92 - 10.69,P = 0.0008)。技术成功率(RR 1.02,95%CI 0.99 - 1.04,P = 0.21)、临床成功率(RR 1.03,95%CI 0.98 - 1.08,P = 0.32)、穿孔(RD 0.01,95%CI -0.03 - 0.02,P = 0.65)、出血(RD 0.00,95%CI -0.03 - 0.03,P = 0.98)、粪便嵌塞(RR 0.56,95%CI 0.12 - 2.04,P = 0.38)和支架阻塞(RR 2.23,95%CI 0.94 - 5.34,P = 0.97)相似。
我们的结果表明,裸支架更具优势,表现为并发症更少、支架迁移率更低、通畅持续时间更长且支架再次置入的需求减少。现有最佳证据主要来自非随机研究;需要更多的随机对照试验。